Table 4.
Incidence rate and SUCRA for the efficacy of treatments to induce end points in the T2DM patients.
| End event | All-cause death | Cardiovascular events | Volume depletion | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment | Event (n) |
Total (n) | Incidence rate (%) | SUCRA (%) |
Event (n) |
Total (n) | Incidence rate (%) | SUCRA (%) |
Event (n) |
Total (n) | Incidence rate (%) | SUCRA (%) |
| Placebo | 1027 | 20916 | 4.91 | 83.0 | 1814 | 16162 | 11.22 | 80.0 | 284 | 15524 | 1.83 | 25.0 |
| Dapagliflozin 2.5mg | 4 | 456 | 0.87 | 89.7 | 12 | 456 | 2.63 | 46.9 | 1 | 456 | 0.22 | 55.0 |
| Dapagliflozin 5mg | 3 | 1020 | 0.29 | 33.7 | 13 | 615 | 2.11 | 23.9 | 11 | 1020 | 1.08 | 29.9 |
| Dapagliflozin 10mg | 539 | 10484 | 5.14 | 68.4 | 27 | 1822 | 1.48 | 45.7 | 245 | 11207 | 2.19 | 38.6 |
| Empagliflozin 10mg | 17 | 2534 | 0.67 | 26.3 | 24 | 902 | 2.66 | 30.9 | 29 | 1287 | 2.25 | 30.5 |
| Empagliflozin 25mg | 21 | 2692 | 0.78 | 23.9 | 35 | 1108 | 3.16 | 21.8 | 41 | 1488 | 2.76 | 50.5 |
| Canagliflozin 100mg | 347 | 8128 | 4.27 | 50.6 | 559 | 4645 | 12.03 | 63.1 | 41 | 2814 | 1.46 | 75.1 |
| Canagliflozin 300mg | 5 | 3648 | 0.14 | 24.4 | 14 | 236 | 5.93 | 87.7 | 62 | 2814 | 2.20 | 95.5 |
The graphs display the distribution of probabilities of treatment ranked from best to worst for each outcome. The ranking indicates the probability that the drug class is first “best,” second “best”, etc. For example, the ranking suggests that dapagliflozin 2.5mg posed the highest risk for incurring all-cause death (worst), while empagliflozin 25mg incurred the lowest probability of all-cause death (best).